Micromet is a German biotechnology company specializing in the development of bispecific antibodies (BiTE) for cancer immunotherapy. The focus was particularly on the active ingredient blinatumomab, which was developed for the treatment of hematological cancers. In 2012, the company was acquired by the US pharmaceutical group Amgen, integrating Micromet into Amgen's global development and marketing strategy. This exit enabled the further development of BiTE technology on an international level.
